Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression.

TMPRSS2-ERG gene fusions that occur frequently in human prostate cancers can be generated either through insertional chromosomal rearrangement or by intrachromosomal deletion. Genetically, a key difference between these two mechanisms is that the latter results in deletion of a ∼3-Mb interstitial region containing genes with unexplored roles in prostate cancer. In this study, we characterized two mouse models recapitulating TMPRSS2-ERG insertion or deletion events in the background of prostate-specific PTEN deficiency. We found that only the mice that lacked the interstitial region developed prostate adenocarcinomas marked by poor differentiation and epithelial-to-mesenchymal transition. Mechanistic investigations identified several interstitial genes, including Ets2 and Bace2, whose reduced expression correlated in the gene homologs in human prostate cancer with biochemical relapse and lethal disease. Accordingly, PTEN-deficient mice with prostate-specific knockout of Ets2 exhibited marked progression of prostate adenocarcinomas that was partly attributed to activation of MAPK signaling. Collectively, our findings established that Ets2 is a tumor suppressor gene in prostate cancer, and its loss along with other genes within the TMPRSS2-ERG interstitial region contributes to disease progression. Cancer Res; 76(7); 1869-81. ©2016 AACR.

[1]  Zhe Li,et al.  RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells , 2014, eLife.

[2]  F. Brimo,et al.  The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature. , 2014, Human pathology.

[3]  I. Mills Maintaining and reprogramming genomic androgen receptor activity in prostate cancer , 2014, Nature Reviews Cancer.

[4]  L. Bubendorf,et al.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer , 2014, Prostate Cancer and Prostatic Disease.

[5]  M. Rubin,et al.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jennifer R. Rider,et al.  Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. , 2013, Journal of the National Cancer Institute.

[7]  R. Cardiff,et al.  ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer , 2013, Proceedings of the National Academy of Sciences.

[8]  V. Reuter,et al.  TMPRSS2–ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry , 2013, Histopathology.

[9]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[10]  Diane D. Liu,et al.  ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[11]  Gerald C. Chu,et al.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. , 2013, Cancer research.

[12]  M. Loda,et al.  ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. , 2013, Genes & development.

[13]  M. Meyerson,et al.  Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential , 2012, Science.

[14]  Jennifer R. Rider,et al.  The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[15]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.

[16]  L. Tran,et al.  Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. , 2012, Cancer research.

[17]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[18]  T. Tsuzuki,et al.  ERG gene rearrangement status in prostate cancer detected by immunohistochemistry , 2011, Virchows Archiv.

[19]  J. Hicks,et al.  Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas , 2011, The American journal of surgical pathology.

[20]  L. Tran,et al.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. , 2011, Cancer cell.

[21]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[22]  P. Jedlicka,et al.  Ets2 Regulates Colonic Stem Cells and Sensitivity to Tumorigenesis , 2011, Stem cells.

[23]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[24]  S. Varambally,et al.  Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.

[25]  Andrew R. Gehrke,et al.  Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo , 2010, The EMBO journal.

[26]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[27]  Markus Reischl,et al.  ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor , 2010, Modern Pathology.

[28]  A. Malek,et al.  ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer , 2010, PloS one.

[29]  O. Witte,et al.  Isolation, cultivation and characterization of adult murine prostate stem cells , 2010, Nature Protocols.

[30]  W. Linehan,et al.  Inhibition of Tumor Cell Motility by the Interferon-inducible GTPase MxA* , 2009, Journal of Biological Chemistry.

[31]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[32]  T. Golub,et al.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.

[33]  R. Shah,et al.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.

[34]  M. Teixeira,et al.  Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. , 2008, The American journal of surgical pathology.

[35]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[36]  G. Jenster,et al.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.

[37]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[38]  A. Evans,et al.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.

[39]  Lynette M. Smith,et al.  N‐cadherin switching occurs in high Gleason grade prostate cancer , 2006, The Prostate.

[40]  M. Bustin,et al.  Chromosomal protein HMGN1 modulates the expression of N‐cadherin , 2005, The FEBS journal.

[41]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[42]  W. Muller,et al.  Ets2-dependent microenvironmental support of mouse mammary tumors , 2005, Oncogene.

[43]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Jose J. Galvez,et al.  Prostatic intraepithelial neoplasia in genetically engineered mice. , 2002, The American journal of pathology.

[45]  C. Hauser,et al.  Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness , 2000, Oncogene.

[46]  Inge Jonassen,et al.  ERG upregulation and related ETS transcription factors in prostate cancer. , 2007, International journal of oncology.